Clinical trials: Influenza, completed
Flu, Human
Factors Influencing Flu Vaccination in Primary Health Care
This study aims to study the barriers to flu vaccination among at-risk people at the Primary Health Care level in order to increase the vaccination rates as recommended by the World Health Organization.
- Trial name
- FIVA (NCT04097197)
- Testing
- Brief educational intervention
- Where
- Portugal
- Volunteers
- 197 people, healthy volunteers welcome
- Sponsor
- Agrupamento de Centros de Saúde de Dão Lafões
Influenza
Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age
The purpose of this study is to evaluate the immunogenicity and safety of the new influenza vaccine GSK2282512A (FLU Q-QIV) and compare its activity to Sanofi Pasteur's Fluzone® (TIV) in children 6 to 35 months of age.
- Trial name
- NCT01974895
- Testing
- FluLaval® Quadrivalent, Fluzone®
- Where
- 12 sites in United States
- Volunteers
- 316 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human, Arthralgia
An Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neonates and Infants With Influenza Infection
Influenza infection is an important public health priority, with seasonal outbreaks and pandemics causing considerable global morbidity and mortality.
- Trial name
- NCT04494412
- Testing
- Zanamivir
- Where
- 6 sites in Italy, Poland and 1 more
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline
Influenza
Comparison of Safety, Tolerability and Immunogenicity of Influenza Vaccines in Adults and Elderly
The purpose of the study is to evaluate safety, tolerability and immunogenicity (in a subset) following a dose of a trivalent subunit influenza vaccine produced either in mammalian cells or in embryonated hen eggs, in healthy…
- Trial name
- NCT00306527
- Testing
- Cell culture derived influenza vaccine, egg-derived influenza subunit vaccine
- Where
- 5 sites in Poland
- Volunteers
- 2,235 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza A Virus
A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection
The purpose of this study is to evaluate the Pharmacokinetic parameters of JNJ-63623872 in combination with oseltamivir in elderly participants (aged 65 to <= 85 years) compared to adults (aged 18 to <= 64 years) with influenza A…
- Trial name
- NCT02532283
- Testing
- JNJ-63623872, Oseltamivir
- Where
- 68 sites in United States, Australia and 13 more
- Volunteers
- 102 people
- Sponsor
- Janssen Research & Development, LLC
Novel Influenza A, H1N1
Novel Influenza A (H1N1) Surveillance Registry
The demographic characteristics, clinical features, course, and outcomes of severe H1N1 influenza infection requiring intensive care have not been defined rigorously and systematically.
- Conditions
- Novel Influenza A, H1N1, Influenza
- Trial name
- NCT01046331
- Where
- 86 sites in United States
- Volunteers
- 894 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Influenza, Human
Safety and Immunogenicity of the Butantan Quadrivalent Influenza Vaccine
Studies have shown that a broader spectrum influenza vaccine may help in reducing the influenza burden of disease. Butantan Institute is currently developing a quadrivalent influenza vaccine candidate.
- Trial name
- NCT03927131
- Testing
- QIV-IB, TIVV-IB, TIVY-IB
- Where
- 12 sites in Brazil
- Volunteers
- 5,822 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Influenza
Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain
An open-label, dose-ranging influenza challenge study in healthy adult volunteers to determine the optimal infection dose and safety of a recombinant H3N2 (A/Texas/ A/Texas/71/2017 (H3N2, clade 3C3a) influenza strain.
- Trial name
- NCT04978454
- Testing
- Influenza RG-A/Texas/71/2017 (H3N2) Challenge
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Influenza Vaccines
Comparative Immunologic Mechanisms and Microbiome Interactions Following Different Influenza Vaccine Formulations in Older Adults
This prospective, randomized, open-label clinical study aims to evaluate the immunogenicity and underlying immune mechanisms of different influenza vaccine formulations in adults aged ≥65 years.
- Conditions
- Influenza, Influenza Vaccines, Microbiome, Immune Response
- Trial name
- NCT07805837
- Testing
- Standard-Dose Influenza Vaccine, MF59-Adjuvanted Influenza Vaccine, High-Dose Influenza Vaccine
- Where
- South Korea
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Korea University Guro Hospital
Seasonal Influenza, Vaccine
Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions
Evaluation of the safety of Trivalent Subunit Influenza Vaccine Produced either in Mammalian Cell Culture or in embryonated Hen Eggs in subjects 18 years of age and above with and without underlying medical conditions and…
- Trial name
- NCT00560066
- Testing
- Cell-derived influenza vaccine, Egg-derived influenza vaccine
- Where
- 15 sites in Germany
- Volunteers
- 1,398 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
COVID-19, Influenza A
Prospective Clinical Evaluation of COVID/Flu Detect™ Rapid Self-Test in Symptomatic Subjects for Non-Prescription Over-the-Counter (OTC) Use
The goal of this study is to evaluate the performance of the COVID/Flu Detect™ Rapid Self-Test when used in a home-like setting by lay users.
- Conditions
- COVID-19, Influenza A, Influenza B
- Trial name
- NCT06734741
- Testing
- COVID/Flu Detect™ Rapid Self-Test
- Where
- 10 sites in United States
- Volunteers
- 899 people
- Sponsor
- InBios International, Inc.
Influenza, Human
Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates at a Large Retail Pharmacy
This research aims to identify which behavioral science strategies are most effective at increasing flu vaccination rates overall and based on patients' individual characteristics.
- Trial name
- NCT04590066
- Testing
- Flu shot text messages
- Where
- United States
- Volunteers
- 734,383 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Diphtheria, Acellular Pertussis
Immunogenicity & Safety of GSK's Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination Schedules
In this study, infants who were previously vaccinated with hepatitis B vaccine at birth will be randomly allocated into two groups: one group of subjects will receive diphtheria, tetanus, acellular pertussis- hepatitis B…
- Conditions
- Diphtheria, Acellular Pertussis, Tetanus, Haemophilus Influenzae Type b
- Trial name
- NCT00316147
- Testing
- DTPa-HBV-IPV/Hib vaccine
- Where
- 4 sites in India
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections, Influenza
Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and Adolescents
The purpose of this study is to compare two flu vaccines to determine their safety and ability to stimulate an immune response in HIV infected children and adolescents.
- Trial name
- NCT00091702
- Testing
- Cold-adapted live attenuated influenza vaccine (FluMist), Inactivated influenza vaccine (IAIV)
- Where
- 61 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Relapsing Multiple Sclerosis
Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)
The primary objective of this study is to determine the proportion of participants with relapsing multiple sclerosis who experience new and/or increased flu-like symptoms (FLS) after transitioning from nonpegylated IFN-β…
- Trial name
- ALLOW (NCT01939002)
- Testing
- BIIB017, naproxen
- Where
- 38 sites in United States
- Volunteers
- 251 people
- Sponsor
- Biogen
Influenza
Trial to Collect Safety Data and Sera for Immunogenicity Testing
To provide Centers for Biologics Evaluation and Research (CBER) with sera collected from healthy children receiving the 2006-2007 formulation of the inactivated, split-virion influenza vaccine Fluzone® for further study by the…
- Trial name
- NCT00389857
- Testing
- Influenza Virus Vaccine (Fluzone®)
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza A H3N2
Assessment of Wearable Sensors During Experimental Human Influenza Infection (Sigma Plus)
The aim of the study is to investigate disease in volunteers deliberately infected with influenza A(H3N2), including biological markers of inflammation and immune response, and changes in physiological parameters including heart…
- Trial name
- NCT04204993
- Testing
- Lumee Oxygen Platform
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Influenza, Pneumonia
Oseltamivir Randomised Controlled Efficacy Trial
Background In preparation for a global influenza pandemic, there is an urgent need for representative data from populations and settings where the pandemic is most likely to arise.
- Conditions
- Influenza, Pneumonia, Lower Respiratory Tract Infection, Upper Respiratory Tract Infection
- Trial name
- NCT00707941
- Testing
- Oseltamivir
- Where
- Bangladesh
- Volunteers
- 1,190 people
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Influenza
Immunogenicity of a Surface Antigen, Inactivated Influenza Vaccine Formulation 2007-2008
Due to antigenic changes of influenza viruses, the virus strains used in influenza vaccines are adjusted every year according to WHO and CPMP recommendations.
- Trial name
- NCT00518453
- Testing
- Surface antigen inactivated influenza vaccine
- Where
- United Kingdom
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Inactivated Influenza A/H9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory Adults
The purpose of this study is to compare the body's reactions and immune responses after receiving different strengths of a H9N2 influenza virus vaccine with and without an adjuvant given into the arm muscle.
- Trial name
- NCT00133471
- Testing
- Influenza A/H9N2 vaccine, MF59 adjuvant
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.